Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults
- Conditions
- HIV Infections
- Interventions
- Biological: DNA-HIV-PT123 vaccineBiological: Bivalent Subtype C gp120/AS01B vaccineBiological: Bivalent Subtype C gp120/MF59 vaccineBiological: Placebo
- First Posted Date
- 2016-09-26
- Last Posted Date
- 2022-04-29
- Target Recruit Count
- 334
- Registration Number
- NCT02915016
- Locations
- 🇿🇦
Qhakaza Mbokodo Research Clinic CRS, Ladysmith, Kwa Zulu Natal, South Africa
🇿🇦Soweto HVTN CRS, Johannesburg, Gauteng, South Africa
🇿🇦The Aurum Institute Tembisa Clinical Research Centre CRS, Johannesburg, Gauteng, South Africa
Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV
- First Posted Date
- 2016-09-19
- Last Posted Date
- 2024-08-26
- Target Recruit Count
- 84
- Registration Number
- NCT02906007
- Locations
- 🇿🇦
Desmond Tutu TB Centre - Stellenbosch University (DTTC-SU) CRS, Cape Town, Western Cape Province, South Africa
🇿🇦Sizwe CRS, Johannesburg, Gauteng, South Africa
🇭🇹Les Centres GHESKIO Clinical Research Site (GHESKIO-INLR) CRS, Port-au-Prince, Haiti
Novel Mobile Device Application to Improve Adherence
- Conditions
- Pediatric Heart TransplantationPediatric Heart Transplant RecipientsPediatric Cardiac Transplantation
- Interventions
- Other: Teen Pocket PATH® Mobile Application
- First Posted Date
- 2016-09-16
- Last Posted Date
- 2019-12-04
- Target Recruit Count
- 26
- Registration Number
- NCT02904278
- Locations
- 🇺🇸
Emory University School of Medicine: Pediatric Transplantation, Atlanta, Georgia, United States
🇺🇸Boston Children's Hospital: Pediatric Transplantation, Boston, Massachusetts, United States
🇺🇸St. Louis Children's Hospital: Pediatric Transplantation, Saint Louis, Missouri, United States
A Safety Trial to Test MVA-BN(R)-Filo and Ad26.ZEBOV Vaccines in Healthy Volunteers
- Conditions
- Ebola DiseaseMarburg Disease
- Interventions
- Biological: Ad26 Zaire Ebola VaccineBiological: MVA Multi-Filo Ebola Vaccine
- First Posted Date
- 2016-09-08
- Last Posted Date
- 2024-08-19
- Target Recruit Count
- 65
- Registration Number
- NCT02891980
- Locations
- 🇺🇸
Emory University School of Medicine, Atlanta, Georgia, United States
Post-Traumatic Stress Symptoms (PTSS) in Transplant Recipients
- Conditions
- Solid Organ Transplant RecipientsParent(s)/Guardian of Referenced Transplant Recipients
- Interventions
- Other: Assessment of adherence, mental health, behavioral, quality of life and biological constructs
- First Posted Date
- 2016-09-08
- Last Posted Date
- 2019-01-07
- Target Recruit Count
- 124
- Registration Number
- NCT02892266
- Locations
- 🇺🇸
Ronald Reagan UCLA Medical Center: Pediatric Transplantation, Los Angeles, California, United States
🇺🇸Lucile Salter Packard Children's Hospital at Stanford: Pediatric Transplantation, Palo Alto, California, United States
🇺🇸UCSF Benioff Children's Hospital: Pediatric Transplantation, San Francisco, California, United States
Trial to Evaluate Beta-Lactam Antimicrobial Therapy of Community Acquired Pneumonia in Children
- Conditions
- Pneumonia
- Interventions
- First Posted Date
- 2016-09-08
- Last Posted Date
- 2021-02-03
- Target Recruit Count
- 385
- Registration Number
- NCT02891915
- Locations
- 🇺🇸
University of Alabama - Children's of Alabama - Infectious Diseases/Virology, Birmingham, Alabama, United States
🇺🇸University of Louisville School of Medicine - Norton Children's Hospital - Infectious Diseases, Louisville, Kentucky, United States
🇺🇸Washington University School of Medicine in St. Louis - Infectious Diseases, Saint Louis, Missouri, United States
Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants 6 to 24 Months of Age
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Biological: PlaceboBiological: RSV LID cp ΔM2-2 Vaccine
- First Posted Date
- 2016-09-07
- Last Posted Date
- 2021-11-05
- Target Recruit Count
- 17
- Registration Number
- NCT02890381
- Locations
- 🇺🇸
Philadelphia IMPAACT Unit CRS, Philadelphia, Pennsylvania, United States
🇺🇸Univ. of Colorado Denver NICHD CRS, Aurora, Colorado, United States
🇺🇸David Geffen School of Medicine at UCLA NICHD CRS, Los Angeles, California, United States
Evaluating the Safety and Immunogenicity of a Live Attenuated Virus Vaccine to Prevent Influenza H3N2v Disease
- Conditions
- Influenza
- Interventions
- Biological: H3N2v MN 2010/AA ca live attenuated influenza vaccine (LAIV)Biological: H3N2v inactivated subvirion influenza vaccineBiological: Placebo
- First Posted Date
- 2016-08-30
- Last Posted Date
- 2018-05-03
- Target Recruit Count
- 1
- Registration Number
- NCT02883426
- Locations
- 🇺🇸
University of Rochester Medical Center (URMC), Vaccine Research Unit (Outpatient), Rochester, New York, United States
Evaluating the Safety and Immunogenicity of a Tetravalent Dengue Vaccine (TetraVax-DV) TV005 in Flavivirus-Naive Adults 50 to 70 Years of Age
- Conditions
- Dengue
- Interventions
- Biological: TetraVax-DV TV005Biological: Placebo
- First Posted Date
- 2016-08-25
- Last Posted Date
- 2018-04-02
- Target Recruit Count
- 28
- Registration Number
- NCT02879266
- Locations
- 🇺🇸
Center for Immunization Research, Johns Hopkins School of Public Health, Baltimore, Maryland, United States
Partnership for Research on Ebola VACcinations
- Conditions
- Ebola Virus Disease
- Interventions
- Biological: PlaceboBiological: Ad26.ZEBOVBiological: rVSVΔG-ZEBOV-GPBiological: rVSV boostBiological: MVA-BN-Filo
- First Posted Date
- 2016-08-23
- Last Posted Date
- 2024-06-26
- Target Recruit Count
- 4789
- Registration Number
- NCT02876328
- Locations
- 🇬🇳
Landreah, Conakry, Guinea
🇱🇷The Redemption Hospital, Monrovia, Liberia
🇲🇱University Clinical Research Center (UCRC), Bamako, Mali